What is the prevalence of Allan-Herndon-Dudley Syndrome?

Allan-Herndon-Dudley Syndrome (AHDS) is an ultra-rare, X-linked genetic disorder characterized by severe intellectual disability and motor impairment, with an estimated prevalence that remains unknown but is thought to be extremely low. Because it is an X-linked condition, it almost exclusively affects males, with clinical features typically emerging in early infancy.

What is the estimated prevalence and incidence of Allan-Herndon-Dudley Syndrome?

There are no exact epidemiological figures for Allan-Herndon-Dudley Syndrome, as it is classified as an ultra-rare disease. Clinical literature suggests that the condition is likely underdiagnosed, meaning the true prevalence is likely higher than the number of documented cases. Because it is rare, global incidence rates per year have not been established. Within the DiseaseMaps.org community, 8 people with Allan-Herndon-Dudley Syndrome have connected to share their experiences, highlighting the importance of patient registries in better understanding this condition.

How does gender and genetics influence the distribution of Allan-Herndon-Dudley Syndrome?

Allan-Herndon-Dudley Syndrome is caused by mutations in the SLC16A2 gene located on the X chromosome. Because of this inheritance pattern, the disease primarily affects males. Females are typically carriers and usually do not exhibit the severe neurological symptoms associated with the syndrome. The condition is characterized by a specific profile of thyroid hormone abnormalities, which is a key diagnostic marker for clinicians.

Why is it challenging to track the prevalence of Allan-Herndon-Dudley Syndrome?

Several factors contribute to the difficulty in obtaining accurate statistics for Allan-Herndon-Dudley Syndrome:

• Diagnostic Odyssey: The complex, multi-system nature of the disease often leads to initial misdiagnosis as cerebral palsy or other non-specific developmental disorders.


• Lack of Awareness: Due to its status as an ultra-rare condition, many healthcare providers may not be familiar with the clinical presentation of Allan-Herndon-Dudley Syndrome.


• Genetic Testing Access: In many regions, access to specialized genetic sequencing for the SLC16A2 gene is limited, preventing definitive confirmation of cases.

Next steps

• Consult with a clinical geneticist to discuss targeted testing for Allan-Herndon-Dudley Syndrome.


• Connect with the community at DiseaseMaps.org to share insights with others navigating this rare diagnosis.


• Review resources from the NIH GARD to stay updated on the latest clinical trial information.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the guidance of your physician or qualified health provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Allan-Herndon-Dudley Syndrome.


• Orphanet: Prevalence of rare diseases and the description of Allan-Herndon-Dudley Syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #300523 - Allan-Herndon-Dudley Syndrome.